(Q53085410)

11 May 2018

meta-analysis

0 references

title

Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia. (English)

1 reference

11 May 2018

1 reference

dasatinib monohydrate

1 reference

1 reference

1 reference

J Li

1

1 reference

11 May 2018

G Xu

2

1 reference

11 May 2018

S Yu

3

1 reference

11 May 2018

L He

4

1 reference

11 May 2018

L Guo

5

1 reference

11 May 2018

publication date

1 January 2011

1 reference

11 May 2018

Journal of International Medical Research

published in

1 reference

11 May 2018

volume

39

1 reference

11 May 2018

issue

2

1 reference

11 May 2018

page(s)

337-347

1 reference

11 May 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001103900201

10.1177/147323001103900201

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018